Morepen Laboratories Limited — Updates, 17-03-2025: Press Release

Morepen Laboratories Limited has launched Empamore, an innovative treatment aimed at Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). With a significant portion of the Indian population affected by diabetes, Empamore offers high-quality treatment at a much-reduced price point—approximately 90% lower than competing brands—aiming to make diabetes management accessible to millions.

Empamore includes Empagliflozin in varying dosages along with combinations featuring Metformin, manufactured at Morepen's USFDA-approved facilities. This aligns with the company's legacy in diabetes management, showcasing its commitment to affordable healthcare without compromising quality. Morepen, having sold nearly 1.65 billion blood glucose strips and equipped over 12.33 million glucometers, positions itself as a leader in the healthcare sector.

The product not only focuses on glycemic control but also addresses related cardiovascular and renal complications, enhancing its appeal. With Empamore, Morepen reinforces its commitment to empower patients, signaling a positive outlook for future growth in the expanding diabetes market.